#Finland #Tampere #Medical Devices #Bioretec Ltd #Bioretec RemeOs

Bioretec Ltd's Successful Rights Issue

On June 24, 2025, Bioretec Ltd announced the final results of its rights issue, revealing a remarkable level of interest and commitment from investors. The company offered a total of 6,156,618 new shares and received subscriptions for 7,658,836, leading to an oversubscription rate of approximately 124.4%. This point underscores strong market confidence in Bioretec as a player in the medical device industry, particularly known for its innovative biodegradable orthopedic implants.

Specifications of the Offering

The offering consisted of new shares priced at EUR 1.50 each, with nearly 79.3% of the subscribed shares bought using subscription rights. The remaining shares were allocated through a secondary subscription, with the total gross proceeds from the rights issue estimated at EUR 9.2 million. Following this transaction, Bioretec’s total number of shares will increase significantly from 24,626,474 to 30,783,092. This increase represents about 20% of Bioretec's outstanding shares post-offering, showcasing a pivotal moment for the company as it expands its capital base.

Trading and Registration Details

According to the company's announcement, the last day for trading the interim shares on the Nasdaq First North Growth Market is set for June 26, 2025. After registration with the Finnish Trade Register, expected also to take place on the 26th, these interim shares will be merged with the existing shares by June 27, 2025. Trading in the newly issued shares will commence the same day, allowing investors to capitalize on their investments promptly.

Strategic Implications for Bioretec

This rights issue not only strengthens Bioretec's financial standing but also enables it to invest further in its pioneering product lines, notably the RemeOs™ implants, which utilize a unique magnesium alloy. These implants are designed to accelerate healing and eliminate the need for follow-up surgeries, thus offering a promising alternative to traditional titanium hardware. The recent CE mark approval from Europe and the market authorization from the U.S. in early 2023 positions Bioretec for significant growth in the global orthopedic trauma and spine market, estimated to be worth over USD 10 billion.

What Lies Ahead

With this successful rights issue, the company's Board of Directors is set to adapt the subscription prices for share options, reflecting the dilutive impact of the new shares. As indicated, adjustments are conditional on the registration of the new shares, with formal announcements expected following this registration.

Joint Global Coordinators for the offering, Danske Bank A/S and DNB Carnegie Investment Bank AB, alongside legal counsel from Krogerus Attorneys Ltd and Borenius Attorneys Ltd, have played integral roles in facilitating this successful outcome.

The landscape for Bioretec appears optimistic, with increased capital allowing for further innovation and enhanced product offerings. As they continue to push the envelope in orthopedic solutions, stakeholders are keenly attentive to how Bioretec’s advancements will influence the medical device industry and, more broadly, patient care in the ongoing pursuit of Value-Based Healthcare.

For more information on Bioretec and its innovative solutions, visit Bioretec's official website.